OPRX OptimizeRx Corp
Price (delayed)
$8.33
Market cap
$154.02M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.1
Enterprise value
$173.84M
OptimizeRx is a digital health company that provides communications solutions for life science companies, physicians and patients. Connecting over half of healthcare providers in the U.S. and millions of patients
Highlights
The gross profit is up by 38% year-on-year and by 8% since the previous quarter
OPRX's revenue is up by 29% year-on-year and by 4.5% since the previous quarter
OptimizeRx's EPS has increased by 18% from the previous quarter but it has decreased by 7% YoY
The net income is up by 17% since the previous quarter but it has declined by 14% year-on-year
OptimizeRx's quick ratio has decreased by 5% QoQ
Key stats
What are the main financial stats of OPRX
Market
Valuations
Earnings
Shares outstanding
18.49M
Market cap
$154.02M
Enterprise value
$173.84M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.31
Price to sales (P/S)
1.65
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.89
Revenue
$92.13M
Gross profit
$59.38M
Operating income
-$13.71M
Net income
-$20.11M
EBIT
-$13.23M
EBITDA
-$8.9M
Free cash flow
$4.44M
Per share
Balance sheet
Liquidity
EPS
-$1.1
EPS diluted
-$1.1
Free cash flow per share
$0.24
Book value per share
$6.35
Revenue per share
$5.04
TBVPS
$2.99
Total assets
$171.17M
Total liabilities
$54.17M
Debt
$33.19M
Equity
$117M
Working capital
$35.32M
Debt to equity
0.28
Current ratio
2.89
Quick ratio
2.77
Net debt/EBITDA
-2.23
Margins
Efficiency
Dividend
EBITDA margin
-9.7%
Gross margin
64.5%
Net margin
-21.8%
Operating margin
-14.9%
Return on assets
-11.7%
Return on equity
-16.9%
Return on invested capital
-24.5%
Return on capital employed
-8.7%
Return on sales
-14.4%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
OPRX stock price
How has the OptimizeRx stock price performed over time
Intraday
1.83%
1 week
-4.69%
1 month
60.81%
1 year
-25.82%
YTD
71.4%
QTD
-3.81%
Financial performance
How have OptimizeRx's revenue and profit performed over time
Revenue
$92.13M
Gross profit
$59.38M
Operating income
-$13.71M
Net income
-$20.11M
Gross margin
64.5%
Net margin
-21.8%
OPRX's operating margin has surged by 60% year-on-year and by 53% since the previous quarter
The operating income has soared by 51% from the previous quarter and by 48% YoY
The gross profit is up by 38% year-on-year and by 8% since the previous quarter
OPRX's revenue is up by 29% year-on-year and by 4.5% since the previous quarter
Growth
What is OptimizeRx's growth rate over time
Valuation
What is OptimizeRx stock price valuation
P/E
N/A
P/B
1.31
P/S
1.65
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.89
OptimizeRx's EPS has increased by 18% from the previous quarter but it has decreased by 7% YoY
The price to book (P/B) is 70% less than the 5-year quarterly average of 4.3
OPRX's equity is down by 8% year-on-year but it is up by 2.2% since the previous quarter
The stock's P/S is 80% below its 5-year quarterly average of 8.2 and 15% below its last 4 quarters average of 1.9
OPRX's revenue is up by 29% year-on-year and by 4.5% since the previous quarter
Efficiency
How efficient is OptimizeRx business performance
OptimizeRx's ROS has soared by 57% YoY and by 53% from the previous quarter
The ROIC has soared by 50% since the previous quarter and by 29% year-on-year
The return on equity has declined by 16% year-on-year but it rose by 16% since the previous quarter
The return on assets rose by 16% since the previous quarter and by 6% year-on-year
Dividends
What is OPRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for OPRX.
Financial health
How did OptimizeRx financials performed over time
The current ratio has contracted by 11% from the previous quarter and by 4.9% YoY
The total assets has declined by 7% year-on-year but it has increased by 3.6% since the previous quarter
The debt is 72% smaller than the equity
OPRX's debt to equity is down by 10% since the previous quarter and by 3.4% year-on-year
The debt has declined by 10% year-on-year and by 7% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.